Mettler-Toledo International Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports fourth-quarter results. Amounts are in U.S. dollars unless stated otherwise.
Business context
Mettler-Toledo is a global supplier of precision instruments and related services, including laboratory and industrial weighing, analytical and process analytics instruments, product inspection systems, and food-retailing solutions. Sales are diversified by geography and customer; no single customer represented more than 1% of annual sales. Laboratory products contributed about 49% of 2016 sales, industrial products 42%, and retail products 9%.
Financial performance
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Net sales | $2,508.3 million | $2,395.4 million | +5% reported; +7% in local currencies |
| Gross profit / gross margin | $1,435.6 million / 57.2% | $1,352.0 million / 56.4% | Margin +0.8 percentage points |
| Earnings before taxes | $504.2 million | $463.4 million | +9% |
| Net earnings | $384.4 million | $352.8 million | +9% |
| Diluted EPS | $14.22 | $12.48 | +14% |
| Cash provided by operations | $443.1 million | $426.9 million | +$16.2 million |
| Capital expenditures | $124.0 million | $82.5 million | +$41.5 million |
| Cash and cash equivalents | $158.7 million | $98.9 million | +$59.8 million |
| Total debt | $894.0 million | $589.6 million | +$304.4 million |
Operating cash flow less capital expenditures was approximately $319.1 million. Reported working capital was $169.6 million, using the company’s definition that excludes cash and short-term borrowings/current maturities. Year-end total debt less cash was approximately $735.4 million. The $800 million revolving credit facility had about $399.6 million available; the company reported compliance with debt covenants.
Fourth-quarter sales were $709.7 million versus $673.5 million in 2015, and net earnings were $137.8 million versus $123.4 million. Diluted EPS was $5.17 versus $4.44.
Material changes and drivers
- Sales increased across major product categories in local currencies: laboratory +8%, industrial +5%, and retail +6%. Product inspection and laboratory products, particularly pipettes and automated chemistry, were notable growth areas.
- Gross-margin improvement reflected higher volume, favorable price realization, and lower material costs, partly offset by investment in field service.
- All reportable segments increased segment profit. Chinese Operations’ profit rose 14% in U.S. dollars; Western European Operations’ rose 15%. Swiss external-customer sales declined 2% in U.S. dollars.
- Reported sales growth was partly obscured by currency movements; most non-U.S. dollar trading currencies, especially the euro, weakened against the U.S. dollar.
- Capital spending included $37 million to purchase the previously leased pipette manufacturing facility. Investing cash outflow also included the $95.8 million Troemner acquisition and other acquisition payments.
- Debt increased substantially, while the company repurchased $500 million of shares and reduced weighted-average diluted shares to 27.0 million from 28.3 million.
Outlook, commentary, and risks
Management described 2016 market conditions as generally favorable but remained cautious about sales prospects given global uncertainty. It plans to continue investing in sales and service capacity, emerging markets, product innovation, pricing and productivity initiatives, and selective acquisitions. The company expects $65–$75 million of net investment in new or expanded manufacturing facilities over the next two years. No specific 2017 sales or EPS guidance is provided in the filing text.
Key risks include foreign-exchange exposure—particularly the Swiss franc, euro, and U.S. dollar—economic and credit uncertainty in China and other emerging markets, customers delaying capital spending, competitive pricing and margin pressure, reliance on certain suppliers and production sites, cybersecurity and systems disruption, and possible additional tax or environmental liabilities. China accounted for 15% of sales to external customers and about 30% of global production. Management identified no legal proceeding expected to have a material adverse effect; it estimates approximately $0.4 million of compliance costs over the next several years for a New Jersey groundwater site.
Unusual items included an $8.2 million non-cash pension settlement charge and $1.1 million of acquisition transaction costs in 2016. Restructuring charges were $6.2 million, down from $11.1 million in 2015. The company expects adoption of a share-based compensation accounting update in 2017 to reduce its income tax rate by approximately 2% for that year; the revenue-recognition standard effective in 2018 is expected to have an immaterial impact.
Important facts for investors to verify
- How much of reported and local-currency growth is sustainable, particularly in China and other emerging markets, and how currency changes may affect earnings.
- Whether margin gains persist as the company expands sales and service resources and faces competitive pricing pressure.
- Debt and liquidity trends after the increase in borrowings, $500 million of share repurchases, acquisition spending, and elevated capital expenditures.
- The eventual cash and earnings effects of pension obligations, tax examinations and repatriation, and potential environmental remediation.
- Progress and cost of the Blue Ocean systems rollout, including related operational, cybersecurity, and financial-reporting risks.